The 2025-2030 World Outlook for Myasthenia Gravis Drugs - Image 1

Out of stock

This item is currently unavailable

The 2025-2030 World Outlook for Myasthenia Gravis Drugs

Subjects

Out of stock

Price data checked 4 days ago

View at Amazon

One email. No newsletter. No nudges.

Sold out. We send one email the moment it's back. Last time, that took just a day or two.

Out of stock 4 days

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

No price data yet

Price history will appear here once data is collected from Amazon.

Price Distribution

No price data available for histogram

Description

This study covers the world outlook for myasthenia gravis drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of myasthenia gravis drugs as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Alexion Pharmaceuticals, Bausch Health Companies, Catalyst Pharmaceuticals, CSL, Curavac, Cytokinetics, F. Hoffmann-La Roche, Flamel Technologies, Galenica, GlaxoSmithKline, Grifols, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Novartis International, Pfizer, and Shire. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).

Product Specifications

Format: paperback
ASIN: B0CZ2LRTMD
Category: Books > Subjects
Domain: Amazon UK
Release Date: 03 March 2024
Listed Since: 01 May 2024

The 2025-2030 World Outlook for Myasthenia Gravis Drugs

Sold out. We send one email the moment it's back. Last time, that took just a day or two.

Price History & Forecast

Price Distribution

Description

Product Specifications

Similar Products You Might Like

The 2025-2030 World Outlook for Myasthenia Gravis Drug Treatments

The 2025-2030 World Outlook for Myasthenia Gravis

The 2025-2030 World Outlook for Myasthenia Gravis Treatments

The 2023-2028 Outlook for Myasthenia Gravis in India

A Look into Myasthenia Gravis

Ocular Myasthenia Gravis (Experts' Perspectives on Medical Advances)

Myasthenia Gravis, Part A: Volume 182 (International Review of Neurobiology, Volume 182)

Myasthenia Gravis, Part B: Volume 183 (International Review of Neurobiology, Volume 183)

The 2025-2030 World Outlook for Spinal Muscular Atrophy

Novel Challenges in Myasthenia Gravis

Myasthenia Gravis and Related Disorders (Current Clinical Neurology)

Myasthenia Gravis and Related Disorders (Current Clinical Neurology)

The 2016-2021 Outlook for Multiple Sclerosis Therapeutics in the United States

The 2025-2030 World Outlook for Muscle Stimulation Devices

The 2013-2018 Outlook for Lou Gehrig's Disease Drugs in India

Myasthenia Gravis and Related Disorders (Current Clinical Neurology)

The 2025-2030 World Outlook for Lou Gehrig's Disease Drugs

The 2023-2028 Outlook for Intravenous Immunoglobulin for Guillain-Barre Syndromes in the United States

The 2023-2028 World Outlook for Guillain-Barre Syndrome Therapeutics

The 2025-2030 World Outlook for Amyotrophic Lateral Sclerosis

The 2016-2021 Outlook for Lou Gehrig's Disease Drugs in the United States

The 2023-2028 Outlook for Guillain-Barre Syndrome Therapeutics in India

The 2023-2028 Outlook for Anti-Vascular Endothelial Growth Factor Therapy (Anti-VEGF) for Non-Infectious Macular Edema in the United States

Acquired Neuromuscular Disorders: Pathogenesis, Diagnosis and Treatment